Surgeons and Operating Room staff are at increased risk of cancer, cataracts, and infertility due to ionizing radiation exposure
Studies show that long-term, cumulative radiation exposure in the operating room is associated with elevated rates of thyroid and other cancers as well as ophthalmic and reproductive disorders among medical personnel.As the use of fluoroscopy rapidly increases in interventional suites, the need for real-time radiation exposure monitoring and guidance to mitigate harm is critical.
Radalara
Radalara™ is a breakthrough computer vision-powered radiation safety technology designed for interventional suites, offering real-time, predictive alerts to clinicians about their positioning within the X-ray field.Unlike conventional dosimetry and monitoring systems, Radalara proactively calculates and forecasts scatter radiation—enabling immediate behavioral adjustments that reduce cumulative exposure, prevent long-term health consequences, and drive a culture of safety.Radalara recently received IRB approval for clinical investigational use and is not yet available for clinical sale or use in any region.
Please direct all enquiries to our Corporate Development Advisor, Amanda Cooper, by clicking the button below
Radalara Receives IRB Approval at Houston Methodist Hospital
Interventional suites rely heavily on fluoroscopy and other X-ray modalities to guide complex medical and surgical interventions. While indispensable for patient care, these technologies emit ionizing radiation that can scatter and accumulate exposure for operating room (OR) personnel over time — increasing risks such as cataracts, dermatitis, and potential long-term effects for healthcare staff.Traditional radiation-monitoring systems are largely reactive, reporting exposure after the fact and offering limited opportunity for behavioural or procedural adjustment in the moment.The IRB-approved study by Radalara at Houston Methodist Hospital marks a critical advance by applying real-time predictive analytics (via a computer-vision device) to forecast scatter radiation and prompt immediate mitigation actions. By shifting from retrospective to proactive radiation safety, this initiative promises to significantly reduce cumulative occupational exposure for interventional teams — advancing the goal of safer operating rooms.
Radalara Receives IRB Approval for Novel Radiation-Safety Study at Houston Methodist Hospital
Houston, TX October 20, 2025 – Radalara, a pioneering healthcare technology company focused on reducing radiation exposure in interventional suites, today announced the approval of an Institutional Review Board (IRB)-approved study at Houston Methodist Hospital. This milestone marks a significant step forward in validating Radalara's innovative computer vision device, which uses predictive analytics to forecast potential scatter radiation and enhance safety for operating room (OR) personnel from the dangers of ionizing radiation.Houston Methodist Hospital, ranked as the top hospital in Texas by U.S. News & World Report , is renowned for its cutting-edge research and commitment to patient and staff safety. The study will test Radalara's proactive technology in real-world interventional procedures, where X-ray exposure poses ongoing risks to medical teams.Radalara (Radiation As Low As Reasonably Achievable) addresses a critical gap in current radiation monitoring systems, which are often reactive and report exposures after the fact - sometimes months later. The Radalara device predictive software allows users to modify behaviors and minimize exposure prior to the radiating event."Partnering with a top-tier institution like Houston Methodist underscores the potential of Radalara to transform radiation safety in healthcare," said Ezekiel Fink, MD, Co-Founder of Radalara. "As a fluoroscopy expert, I am concerned about the long-term health impacts of cumulative low-dose radiation on vast numbers of healthcare professionals who work in close proximity to radiation and patients who are exposed to radiation in medical settings. This IRB-approved study will provide essential data to refine our technology with the goal of improving safety ."The company has a working prototype, multiple patents filed with a filed non-provisional patent granted, and a clear path to FDA approval.About RadalaraRadalara, a Helios Inno company, is dedicated to advancing radiation safety through innovative, predictive technology. By enabling real-time exposure reduction, we protect healthcare professionals and improve outcomes in interventional suites.Media Contact:
Dr. Ezekiel Fink
HSPM Group
© Radalara, a Helios Inno company. All Rights Reserved.